These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 7259534)

  • 21. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
    Schwandt P; Weisweiler P; Drosner M; Janetschek P
    Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
    [No Abstract]   [Full Text] [Related]  

  • 22. [Longterm therapy and etofibrate (author's transl)].
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P
    MMW Munch Med Wochenschr; 1980 Jan; 122(3):95-8. PubMed ID: 6767931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
    Wechsler JG; Hutt V; Klör HU; Ditschuneit H
    Artery; 1980; 8(6):519-29. PubMed ID: 7259531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP; Loewer H; Suermann I
    Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
    Lang PD; Vollmar J
    Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
    Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
    Reuter W
    Z Alternsforsch; 1982; 37(6):409-16. PubMed ID: 7164480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB; Peters JR
    Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
    Vessby B; Lithell H; Ledermann H
    Atherosclerosis; 1982 Jul; 44(1):113-8. PubMed ID: 7115473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W; Schilling A; Calder D
    Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
    Wirth A; Middelhoff G; Braeuning C; Schlierf G
    Atherosclerosis; 1982 Dec; 45(3):291-7. PubMed ID: 7159500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of various types of hyperlipoproteinaemia with a combination of Mg-chlorophenoxy-isobutyrate and mesoinositol-hexanicotinate (author's transl)].
    Bolzano K; Krempler F; Haslauer F
    Arzneimittelforschung; 1979; 29(10):1621-4. PubMed ID: 583231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 37. [Modification of pathologic fatty acid patterns in old age by combined clofibrinic and nicotinic acid treatment].
    Reuter W
    Z Alternsforsch; 1983; 38(5):383-8. PubMed ID: 6659567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ; Gutiérrez Martín M; del Río Ligorit A; Casasnovas Lenguas JA; Cornudella Lacasa R
    Med Clin (Barc); 1982 May; 78(9):380-5. PubMed ID: 7047926
    [No Abstract]   [Full Text] [Related]  

  • 39. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia.
    Ferreira IJ; del Rio A; González-Viejo N; Vicens B
    Arzneimittelforschung; 1981; 31(10a):1859-62. PubMed ID: 7032533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.